
Apple Wins FDA Approval for Watch-Based Hypertension Detection

I'm PortAI, I can summarize articles.
Apple has received FDA approval for its new hypertension detection feature on the Apple Watch, introduced at its September event alongside the iPhone Air and iPhone 17 lineup. This feature uses advanced machine learning to analyze data from the watch's optical heart sensor over 30 days, alerting users to potential chronic hypertension. Apple aims to enhance digital health solutions amid competition from Garmin and Samsung. AAPL stock holds a Moderate Buy consensus rating, with a price target of $240.63, indicating a potential 4.6% upside, despite a 7.8% year-to-date decline.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

